Intellectual Property in Medical Imaging and Informatics: The Independent Inventor’s Perspective by Reiner, Bruce I.
Intellectual Property in Medical Imaging and Informatics:
The Independent Inventor’s Perspective
Bruce I. Reiner
1,2
While innovation and new product development is
traditionally thought of as the exclusive domain of
industry and academia, a large number of innovations
in medicine and information technology have come from
independent inventors, which account for almost 30%
of new patents issued in the U.S. today. A large number
of economic, political, and legal challenges exist within
the current marketplace that serves as relative impedi-
ments to independent invention. This article explores the
existing challenges facing the independent inventor and
offers a number of recommendations and resources to
facilitate independent inventors in their quest for inno-
vation and entrepreneurship. The concept of “outsourc-
ing innovation” is discussed as an alternative to the
existing model of industry sponsored research and
development (R&D), with the goal of combining the
unique attributes and strengths of independent inventors
and industry sponsors.
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Learning and innovation go hand in hand.
The arrogance of success is to think that
what you did yesterday will be sufficient
tomorrow. William Pollard
INTRODUCTION
I
ntellectual property (IP) is defined as property
that can be protected under federal law,
including copyrightable works, ideas, discoveries,
and inventions.
1 Most research and publications on
IP focus on technological development within
companies and industries
2,3 and on academic and
government laboratories.
4,5 This focus is both the
result of and reinforcement for the misconception
that modern technological innovation is the pur-
view of industry and academia.
In reality, many of the most influential and
innovative medical and information technology
(IT) inventions have been created by independent
inventors, including: Wilson Greatbatch, who
patented the implantable cardiac pacemaker;
Raymond Damadian first described the concept
of nuclear magnetic resonance and patented the
first commercial unit; Raymond Kurzweil patented
and marketed the first omnifont optical character
recognition system and numerous speech recogni-
tion innovations; and Linus Torvalds wrote the
program that became the Linux kernel.
Despite the many remarkable achievements of
independent innovators, numerous technical, eco-
nomic, political, legal, and educational challenges
confrontindependentinvention.Thisarticleiswritten
to serve as an educational resource and guide to the
fledgling independent inventor in imaging informat-
ics, with the hope of encouraging entrepreneurship,
innovation, and creativity within the existing con-
straints of a field dominated by industry-initiated
research and development (R&D).
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The U.S. Patent and Trademark Office (USPTO)
defines an independent inventor as one whose
patent (at the time of issuance) is unassigned or
assigned to an individual. The percentage of
patents issued to independent inventors declined
from 36.4% in 1987 to 26.8% in 1999.
6 Interna-
tional patent data (1999) show great variability in
the overall percentages of patents issued to
independent inventors, with less industrialized
countries having a higher percentage of indepen-
dent invention (75% in Hungary and 66% in
Brazil, for example), compared with more indus-
trialized countries (26% in both the United
Kingdom and United States
6).
Although the relative percentage of patents
issued to independent inventors has gradually
decreased over time, the total number of patents
awarded to independent inventors increased by
approximately 30% from 1990 to 2000.
7 These
figures suggest that independent invention is alive
and well in the United States and retains a vital
role in innovation throughout industry and the
marketplace.
A recent survey published by Weick and Eakin
8
explored the role and economic viability of inde-
pendent inventors in the United States. Survey data
revealed 83% of independent inventor respondents
were “part-time” inventors, and 17% were “full
time” inventors. Eighty-four percent of inventor
respondents reported developing working proto-
types of their inventions within the past 5 years.
The top invention categories were dominated by
hardware/tools, household, and industrial/commer-
cial products, and the most frequently cited scien-
tific/technology inventions were categorized as
electronics (13%) and medical/therapeutic (12%).
Thirty-nine percent of respondent inventors
reported generating sales from their inventions
(mean sales, $3.5 million; median sales, $50,000),
and 22% reported profitability (mean profit, $1.96
million; median profit, $75,000). The three principal
means of IP commercialization included develop-
ment of start-up companies (55% of respondents),
licensing IP to another company (44% of respon-
dents),andoutrightsales ofIP(16%ofrespondents).
Inventors who elected to license their inventions to
others were more likely to achieve a higher level of
overall sales than those attempting to commercialize
the IP themselves or who sold the IP to a third party.
This corroborates previously reported findings by
Khan and Sokoloff,
9 who reported independent
inventors’ commercial success to be greatest
through licensing agreements.
Existing Limitations of Industry-Sponsored
R&D
The prevalent paradigm of industry-sponsored
R&D suffers from several limitations, some of
which are outlined in Table 1. The various
strengths that provide industry with a distinct
(and arguably unfair) advantage over the indepen-
dent inventor paradoxically provide a disincentive
toward innovation. This can be explained in part
by the life cycle of innovation embraced by many
companies, particularly larger and more financially
successful concerns.
In the first stage (infancy) of this life cycle,
innovation plays the dominant role in creating new
IP, a process that provides the impetus and backbone
for the original creation of many companies. The
fledgling company is founded by a few energetic,
industrious, and optimistic inventors who, through a
combination of idealism, capitalism, and naivety,
decide to embark on the development of a start-up
company despite long odds against success. In the
second stage (childhood), the company grows
through successful commercialization of their inno-
vation and IP. As the company grows and achieves
economic success, the culture begins to shift from
optimism and innovation to pragmatism and risk
aversity. The political and economic realities of the
marketplace begin to surface, and the founders of the
company often turn over operational control to
financial and management “professionals.” If the
company continues on a path of relative indepen-
dence(avoidingmergeroracquisition)andcontinues
to achieve greater success in the marketplace, it may
then enter stage 3 (adulthood), in which it is often
transformed from “innovator” to “predator.” In
Table 1. Existing Limitations of Industry-Sponsored R&D
Limitation
A follow-the-pack (lemming) mentality
Small, incremental approaches to new IP
Internal corporate politics and constraints
Short-term outlook targeted at immediate gratification
Product development done in “back rooms”
Limited input from “frontline” users
Reactive, not proactive, approach to market needs
4 REINERentering this stage, the company often grows by
acquiring smaller (and more innovative) companies,
thereby expanding its product line and IP pipeline.
The large “predatory” company now responds to
market economics, with product development large-
ly dictated by the perceived needs of the customer
base. Invention is typically performed within the
company (“in house”) by individuals who are often
constrained by company politics and the economics
of immediate gratification. The typical corporate
mindset is to “play not to lose” rather than “play to
win”. As a result, innovation is largely stifled and
relegated to product line developments and “incre-
mental” improvement. It is ironic that the very
company that was initially created by innovation
and creativity becomes transformed into one that
strives to stifle (and often crush) the creativity of the
independent (and innovative) inventor.
In this life cycle, inventors themselves are no
longer frontline users but, instead, are technicians
and engineers. In the medical domain, these
engineers are, for the most part, technology savvy,
but clinically uninformed. As a result, refinements
and new developments are based, at best, on
minimal knowledge of how the product will truly
function in the clinical environment. When clinical
input is included, it is typically done by “experts”
on a medical advisory board who have little
practical experience outside of academia. As a
result, even with a gloss of medical input, many
products are developed within a rigid corporate
culture by nonclinicians who are highly risk averse
and focused on short-term horizons.
Theindependentinventor,ontheotherhand,isnot
boundbythesamecorporateconstraintsand,instead,
can bring a fresh and practical perspective to product
innovation. This strategy of “outsourcing innova-
tion” is uncommon within industry today but offers
the potential to create new independent inventor–
industry synergies. The creation of an open market
approach to innovation provides a cost-effective and
practical means for companies to remove their self-
induced IP constraints and seek out inventors from
external sources to enhance innovation within new
and existing product lines.
10,11
Defining the Invention Process
Table 2 outlines a ten-step iterative process for
invention and product development. The first step
is to define an existing problem or deficiency in
everyday practice. One example comes from my
own work in private practice radiology, where one
of my biggest concerns is the paucity of objective
quality assurance (QA) metrics and standards
within medical imaging and the lack of supporting
technology. With the sole exception of mammog-
raphy,
12 no medical imaging modality has rigorous
and mandatory QA standards, despite a broad
agreement on the significance of the role of
medical imaging QA in clinical and economic
outcomes.
13 Simply stated, QA in its present form
is largely idiosyncratic and often nonexistent.
In attempting to objectively quantify existing QA
practice, we performed several studies evaluating
QA-related workflow, technology, and variability
and the related effects on image quality.
14–17 The
results have indicated that the current practice of
medical imaging QA is fraught with error and
inconsistencies, resulting in inefficient workflow,
reduced technologist productivity, poor image
quality, and suboptimal radiation dose to patients.
The data call for a complete revamping in the
clinical and technical ways in which QA activities
are implemented.
Defining the solution becomes fairly straightfor-
ward when confronted with the paucity of data,
lack of standards, wide inter- and intradepartmen-
tal variability in performance, and lack of support-
ing technology for QA assessment. The ideal
solution to improve current inefficiencies would
be an automated system to record, measure, track,
analyze, and provide QA feedback to practitioners.
After identifying and defining this deficiency, I
proposed and described one such solution and
submitted it for review by the USPTO. Although
the idea may appear sound, it is only as good as
the working prototype. As an independent inven-
tor, I did not have the technical or economic
resources required to create a working prototype
Table 2. Stepwise Approach to Invention Process
Approach
Define an existing problem or question
Review the current technical solution
Identify existing limitations and inefficiencies
Collect data using existing technology
Devise an alternative solution (invention)
Develop a prototype
Collect data using the prototype
Refine the prototype based on data and end-user feedback
Repeat data collection (and refinement as necessary)
Commercialize invention
INTELLECTUAL PROPERTY IN MEDICAL IMAGING AND INFORMATICS 5and, therefore, elected to seek industry partnership
through a licensing agreement. The project is far
from complete, but the sequence of events outline
in Table 2 are those that I have come to recognize
as requisite for creation and implementation of an
invention, with the ultimate goal of creating
independent inventor–industry collaboration and a
final product based on a data-driven engineering
process.
18
Practical Advice for Inventors
Table 3 is a list of practical suggestions for the
independent inventor. First and foremost is the
reality that inventorship is equivalent to running a
marathon, not a sprint. Even under the best of
circumstances, the patent review process takes 2–
3 years and often longer, depending on the USPTO
backlog, the initial review of the patent examiner,
and what “prior art” (previously filed similar or
analogous patents) is identified in the search
process. Once the review process has been
completed, the inventor must begin the arduous
task of marketing the invention and/or developing
a prototype. Because of the intensive resource
requirements for prototype development, many
inventors elect to pursue a licensing agreement
with an established company that has the technical,
financial, personnel, and legal resources to com-
mercialize the patent and defend against potential
future litigation. Securing a patent does not
preclude the appearance of a predatory company
that commits infringement. The best deterrent is an
ally with deep pockets and the combined economic
and legal clout to punish any violators.
The patentapplicationprocess inthe UnitedStates
typically costs in the range of $20,000–$30,000. The
result is that many independent inventors are forced
either to abandon their IP or seek external funding
sources. Although third parties exist in the form of
independentinvestorandventurecapitalistconsortia,
the inventor sometimes forfeits substantial economic
and legal rights in entering such agreements. Having
sound legal advice with expertise in patents and
licensing is critical in ensuring that the best interests
of the inventor (and the long-term security of his or
her IP) are protected. New legislation is currently
pending in Congress (HR 2795) that calls for major
patent reforms. Enactment of this legislation could
havenegativeeffectsontheindependentinventorby:
1. Changing the definition of inventor from “first
to invent” to “first to file”;
2. Limiting a patent holder’s rights to obtain a
permanent injunction against an offending third
party;
3. Creating a post-patent grant opposition pro-
ceeding; and
4. Limiting damages for infringement lawsuits
In the end, larger corporations and academic
institutions have far more extensive resources and
expertise to create, manage, and defend patents.
These disproportionate resources should not pre-
clude the independent inventor from seeking
patents but should provide significant incentives
to pursue symbiotic partnerships with industry that
can ultimately benefit both parties.
Although “do it yourself” programs are widely
advertised as ways for independent inventors to draft
their own patent applications, investors should be
wary of the long-term ramifications of even minor
errors in the patent process. Claim wording on
patents is complex and most properly the province
of specialized attorneys with extensive training and
experience. The prior art search is another integral
component of patent preparation that should be
Table 3. Practical Advice for Inventors
Advice
Expect success to take 5–10 years
Do not quit your day job
Engage professional legal services for
Prior art search
Patent preparation
Nondisclosure agreements
Commercialization
Document everything!
Do not market until you receive notice of allowance
Be a little paranoid; expect dishonesty
File a provisional patent ASAP
Consider licensing as a means to commercialize
Leverage existing practical knowledge and experience
Think out of the box!
Leverage existing resources
Table 4. Existing Resources for the Independent Inventor
Resource Url
U.S. Patent & Trademark Office http://www.uspto.gov
United Inventors Association http://www.uiausa.org
Inventor Ed Inc. http://www.inventored.org
Invent Net http://www.inventnet.com
Index to U.S. Patent
Classification
http://www.ibiblia.org/
patents/index.html
Lemelson Foundation http://www.lemelson.org
6 REINERperformedbyskilledand experiencedpersonnel.Itis
also essential to have the representation of a
dedicated attorney in negotiating potential partner-
ships and collaborations, particularly in drafting a
well-constructed nondisclosure agreement (NDA),
which serves to protect the IP of both parties.
Trust and loyalty are admirable qualities, but the
independent inventor must be cautious when discus-
sing and exchanging IP. This takes on even greater
importance with the impending Congressional legis-
lation that providesIPownership tothe “first tofile”,
as opposed to the traditional “first to invent.” An
independent inventor should, therefore, forego dis-
cussions related to “new” IP until after a provisional
patent has been submitted and then only with a
mutually signed NDA. To quote Andy Grove,
former CEO of Intel, “only the paranoid survive.”
In the event that patent litigation occurs and two
parties are vying for patent ownership, or one party
is challenging the validity of a recently issued
patent, the courts will look for dated documenta-
tion to determine which party was “first to invent.”
As a result, it is imperative that the independent
inventor document everything related to the inven-
tion from concept creation, to embellishment, to all
forms of communication with third parties.
Most important, the intrinsic value of one’s own
creativity, practical knowledge, and experience
should not be underestimated. Having the luxury
of being independent and unconstrained by corpo-
rate shackles can be a distinct advantage to the
independent inventor. In-house patent applications
must pass through serial scrutiny that often serves
to squash innovation and unorthodox thinking.
The independent inventor does not have these
limitations and is, instead, free to explore any and
all creative concepts, regardless of the existing
product pipeline. Although market viability and
compatibility with a company’s strategic planning
remain critical points of analysis for potential
inventor–industry partnerships, the independent
inventor should continuously strive to “push the
envelope” and leverage his or her own unique
insights and experience.
The new independent inventor should take
advantage of existing resources that can provide
valuable insights, contact information, and educa-
tional programs. Several of these Internet-based
resources are listed in Table 4 and serve merely as
starting points in the quest for inventor knowledge
and experience. Although the barrier to entry as an
inventor is high, success can be achieved by those
with insight, creativity, and perseverance.
CONCLUSION
Despite the economic and legal impediments
facing IP development in the current marketplace,
many important innovations and technologic
breakthroughs within medicine are the result of
independent inventors. These independent inven-
tors play a unique and vital role towards IP
development in medical imaging and information
technology through their practical first-hand expe-
rience, “out of the box” mentality, and proactive
perspective. They are not restricted by many of the
traditional constraints existing within an industry
including the incremental approach to product
development, internal politics, and a short-term
focus on return on investment (ROI). The tradi-
tional paradigm of industry-sponsored R&D may
be better served through the creation of a more
collaborative approach of “outsourcing innova-
tion”, thereby creating a synergy between inde-
pendent inventors and industry sponsors. In the
end, innovation can be better served by creating an
atmosphere for open competition, creativity, and
accountability.
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